Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides - Report - MDSpire

Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides

  • By

  • Sheng-Guang Li

  • Yadan Zou

  • Ji Li

  • Lina Zhang

  • Jing Zhang

  • Ting Long

  • Ruohan Yu

  • Yanfeng Zhang

  • June 4, 2026

  • 0 min

Share

Safety of Biologic and Targeted Therapies in Relation to Tumor Risk

Overview

Expand on the specific high-risk populations for JAK inhibitors, such as older patients and those with a history of malignancy.

Background

Immune-mediated inflammatory arthritides (IMIA) are chronic conditions that can increase cancer susceptibility due to persistent inflammation and immunosuppressive treatments. Understanding the malignancy risks associated with biologic and targeted therapies is crucial for optimizing treatment strategies in these patients. Recent evidence highlights the need for individualized treatment approaches, particularly for those with a history of malignancy.

Data Highlights

Remove placeholder text and clarify that no specific numerical data is provided.

Key Findings

Rephrase findings for clarity and ensure they are directly supported by the source material.

Clinical Implications

Highlight the need for monitoring specific malignancy types associated with each therapy.

Conclusion

The safety of biologic and targeted therapies in relation to tumor risk in IMIA requires careful consideration of individual patient profiles. A balanced approach is necessary to manage inflammation while minimizing oncologic vulnerability.

Related Resources & Content

  1. EULAR, 2024 -- 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
  2. Sebbag et al, Annals of the Rheumatic Diseases, 2024 -- Balancing Treatment Risks for Inflammatory Arthritis and Cancer
  3. Drug Safety, 2023 -- Balancing Cardiovascular and Cancer Risks in the Use of JAK Inhibitors
  4. Frontiers in Immunology — Navigating renal safety in the biologic treatment of psoriasis: from immunologic mechanisms to clinical practice
  5. Clinical Rheumatology — Characterizing the Efficacy of TNF-Inhibitors in Rheumatoid Arthritis: The Adverse Effects of Anti-TNF Cycling and the Importance of a Tailored Approach for Identifying Primary Non-Responders
  6. Navigating renal safety in the biologic treatment of psoriasis
  7. Characterizing the Efficacy of TNF-Inhibitors in Rheumatoid Arthritis
  8. Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors
  9. 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer | Annals of the Rheumatic Diseases
  10. Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta-Analysis - PubMed
  11. Frontiers | Efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors for psoriatic arthritis: a network meta-analysis of randomized controlled trials

Original Source(s)

Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides

  • by Sheng-Guang Li, Yadan Zou, Ji Li, Lina Zhang, Jing Zhang, Ting Long, Ruohan Yu, Yanfeng Zhang

  • June 4, 2026

Related Content

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

Rehab May Improve Function in AS

Supervised rehabilitation and exercise-based therapies may improve function, pain, and bone health in ankylosing spondylitis, according to a new review.

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models